Article Text

Download PDFPDF

208:poster Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: an economic evaluation of the INTRO-HCV trial
  1. Aaron G Lim1,
  2. Christer Frode Aas2,3,
  3. Ege Su Çağlar2,3,
  4. Jørn-Henrik Vold2,3,
  5. Lars Thore Fadnes2,3,
  6. Kjell Arne Johansson2,3,
  7. Peter Vickerman1
  1. 1Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
  2. 2Bergen Addiction Research group, Department of Addiction Medicine, Haukeland University Hospital, Østre Murallmenningen 7, N-5012 Bergen, Norway
  3. 3Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway


Introduction People who inject drugs (PWID) have the highest burden of hepatitis C virus (HCV) globally, but are often undertreated due to stigma and lack of access to services. The INTRO-HCV randomised control trial conducted in Norway over 2017-2019 found that integrating HCV treatment, using direct-acting antivirals (DAAs), among PWID in community settings improved treatment outcomes, but did not compare longer-term health economic benefits. This study analyses the cost-effectiveness of integrated treatment compared to standard referral pathway.

Methods A health state transition Markov model of HCV disease progression and treatment was developed based on the INTRO-HCV trial. Treatment unit costs and health-related quality of life outcome data were derived from the trial and used to parameterise the model. The incremental cost-effectiveness ratio (ICER) was calculated in terms of cost per quality-adjusted life year (QALY) gained from the health provider’s perspective over a lifetime horizon and compared against a conventional (NOK 500,000) willingness-to-pay (WTP) threshold for Norway. Probabilistic and univariate sensitivity analyses were undertaken, focussing on DAA price reductions.

Results Compared to standard treatment, integrated treatment resulted in an ICER of NOK 213,498/QALY gained, with 90.8% probability of being cost-effective against the conventional WTP threshold. Sensitivity analyses suggest that cost of DAA medications strongly affected the ICER, with 30% lower DAA price resulting in integrated treatment having an ICER of NOK 91,825/QALY gained and 98.9% probability of being cost-effective. A 60% lower DAA price led to negative ICER of NOK -20,607/QALY gained, with 100% probability of being cost-effective and 66.8% probability of being cost-saving. A 90% lower DAA price had negative ICER of NOK -140,205/QALY gained and 100% probability of cost-saving.

Discussion Integrating HCV treatment for PWID in community settings is likely to be highly cost-effective and may become cost-saving even with moderate reductions in DAA price.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: .

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.